TY - JOUR
T1 - Hemostatic abnormalities in patients with congestive heart failure
T2 - Diagnostic significance and clinical challenge
AU - Davis, Christopher J.
AU - Gurbel, Paul A.
AU - Gattis, Wendy A.
AU - Fuzaylov, Sergey Y.
AU - Nair, Girish V.
AU - O'Connor, Christopher M.
AU - Serebruany, Victor L.
N1 - Copyright:
Copyright 2006 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Knowledge of the pathogenesis of congestive heart failure (CHF) has improved greatly in recent years. However, this disease continues to cause one of the highest morbidities and mortalities in the Western world. The pathophysiology of heart failure is complex and much of our understanding revolves strictly around the neurohormonal mechanisms involved. Various pharmacologic interventions have significantly improved morbidity and include ACE inhibitors, β-blockers, diuretics, and inotropic agents. Yet, no consensus has been reached regarding the use of anticoagulants or antiplatelet agents. It has been suggested that CHF is associated with altered hemostasis, but whether this prothrombotic state contributes to the pathogenesis and progression of the disease is unknown. The purpose of this review article is to discuss our current knowledge of platelet activation, thrombin generation, fibrinolysis, and endothelial dysfunction in CHF patients, and the potential role of anticoagulants and/or antiplatelet agents in preventing these hemostatic abnormalities. Copyright (C) 2000 Elsevier Science Ireland Ltd.
AB - Knowledge of the pathogenesis of congestive heart failure (CHF) has improved greatly in recent years. However, this disease continues to cause one of the highest morbidities and mortalities in the Western world. The pathophysiology of heart failure is complex and much of our understanding revolves strictly around the neurohormonal mechanisms involved. Various pharmacologic interventions have significantly improved morbidity and include ACE inhibitors, β-blockers, diuretics, and inotropic agents. Yet, no consensus has been reached regarding the use of anticoagulants or antiplatelet agents. It has been suggested that CHF is associated with altered hemostasis, but whether this prothrombotic state contributes to the pathogenesis and progression of the disease is unknown. The purpose of this review article is to discuss our current knowledge of platelet activation, thrombin generation, fibrinolysis, and endothelial dysfunction in CHF patients, and the potential role of anticoagulants and/or antiplatelet agents in preventing these hemostatic abnormalities. Copyright (C) 2000 Elsevier Science Ireland Ltd.
KW - Congestive heart failure
KW - Hemostasis
KW - Platelets
UR - http://www.scopus.com/inward/record.url?scp=0033777885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033777885&partnerID=8YFLogxK
U2 - 10.1016/S0167-5273(00)00300-4
DO - 10.1016/S0167-5273(00)00300-4
M3 - Review article
C2 - 11054501
AN - SCOPUS:0033777885
SN - 0167-5273
VL - 75
SP - 15
EP - 21
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -